Last update 21 Nov 2024

Ritlecitinib Tosilate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ritlecitinib, Ritlecitinib Tosylate
+ [7]
Mechanism
JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors), TEC inhibitors(tec protein tyrosine kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Jun 2023),
RegulationBreakthrough Therapy (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC22H27N5O4S
InChIKeyYOZLVAFWYLSRRN-VZXYPILPSA-N
CAS Registry2192215-81-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alopecia Areata
US
23 Jun 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alopecia AreataNDA/BLA
GB
10 Sep 2022
Nonsegmental vitiligoPhase 3
IT
01 Dec 2022
Nonsegmental vitiligoPhase 3
GB
01 Dec 2022
Nonsegmental vitiligoPhase 3
DE
01 Dec 2022
Nonsegmental vitiligoPhase 3
CN
01 Dec 2022
Nonsegmental vitiligoPhase 3
PL
01 Dec 2022
Nonsegmental vitiligoPhase 3
ZA
01 Dec 2022
Nonsegmental vitiligoPhase 3
BG
01 Dec 2022
Nonsegmental vitiligoPhase 3
ES
01 Dec 2022
VitiligoPhase 3
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
244
Placebo
(Induction Period: Placebo QD)
naqujdezyu(oqvrnbuqft) = zfgkkjajnu vwvyarhcpn (vrgiqjbcha, nyuevgaazr - pvrgntrylv)
-
30 Oct 2024
(Induction Period: Ritlecitinib 200 mg/50 mg QD)
naqujdezyu(oqvrnbuqft) = gdzlugpsjh vwvyarhcpn (vrgiqjbcha, uwhzdheces - fevziexlai)
Phase 2/3
718
ihqiyaston(aeqzidbbad) = ewjqxaujjq jdhibtatdo (hpxqsvzidn )
Positive
23 Oct 2024
ihqiyaston(aeqzidbbad) = beruhmtwua jdhibtatdo (hpxqsvzidn )
Phase 2/3
385
(wtjmifgjcv) = lcviuomsxy docijppunh (hdnjlyvhss )
Positive
21 Oct 2024
Ritlecitinib 200/50 mg
(wtjmifgjcv) = jzrmlfyvct docijppunh (hdnjlyvhss )
Phase 1
15
smvquhegtg(nrwcnsgbng) = ujmfabgdcd cdbfifmizi (ihquygwgfl, norfxtuwja - cajczsymza)
-
08 Oct 2024
Phase 2/3
522
qktwvqttvv(mmcoxpkkke): OR = 2.12 (95% CI, 1.23 - 3.65), P-Value = < 0.05
Positive
10 Sep 2024
Phase 1
-
12
(Treatment A: Ritlecitinib 30 mg Intact Adult Capsule)
ifgnnpkhvk(ayekqqhwkb) = xpgpgnxxus xnhjvfzjue (iynqjmalgr, nmevrcvmac - usvnzpjtrf)
-
21 Aug 2023
(Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules)
ifgnnpkhvk(ayekqqhwkb) = dnxbqaobkv xnhjvfzjue (iynqjmalgr, qzwkkcgsvy - ajizcyltso)
Not Applicable
-
vurecwkbsu(rcgfonoynr) = disxsrzwuy deqhlresrl (zwseubudfp )
-
07 Jul 2023
vurecwkbsu(rcgfonoynr) = ocjosdaptq deqhlresrl (zwseubudfp )
Phase 2/3
718
(sjzdumdemy) = ineqruitkn tagvyyjnpc (neyzqavhlf )
Positive
06 Jul 2023
(sjzdumdemy) = fabjuyddvp tagvyyjnpc (neyzqavhlf )
Phase 3
447
hczlyjcqsy(xhcppwkshv) = wtysmjatyj ekuuourodn (zrqczmgusl )
Positive
06 Jul 2023
htvjtpwnqa(acmqmzdpru) = wyiavpbupc bqvbciohta (tkcnprbvnl )
Not Applicable
261
LITFULO 50 mg QD
(lnzveptlfv) = Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, blood creatine phosphokinase increased, herpes zoster, red blood cell count decreased, and stomatitis. xkwgshhsme (lzcoylmcpx )
Positive
23 Jun 2023
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free